Clinical features and diagnostic usefulness of antibodies to clustered acetylcholine receptors in the diagnosis of seronegative myasthenia gravis

JAMA Neurology

Volumn 72, Issue 6, 2015, Pages 642-649

  Cruz, Pedro M Rodríguez ^a,b   Al Hajjar, Michal ^a   Huda, Saif ^a   Jacobson, Leslie ^a   Woodhall, Mark ^a   Jayawant, Sandeep ^c   Buckley, Camilla ^a   Hilton Jones, David ^a   Beeson, David ^b   Vincent, Angela ^a   Leite, Maria Isabel ^a   Palace, Jacqueline ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLINERGIC RECEPTOR ANTIBODY; AUTOANTIBODY; CHOLINERGIC RECEPTOR;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY DETECTION; ARTICLE; BULBAR PARALYSIS; CELL ASSAY; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PHENOTYPE; PREPUBERTY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; RADIOIMMUNOPRECIPITATION; REMISSION; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; THYMECTOMY; TREATMENT RESPONSE; YOUNG ADULT; BIOASSAY; DIAGNOSTIC USE; IMMUNOLOGY; ONSET AGE; PATHOPHYSIOLOGY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; STANDARDS;

ADOLESCENT; ADULT; AGE OF ONSET; AUTOANTIBODIES; BIOLOGICAL ASSAY; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; MYASTHENIA GRAVIS; PHENOTYPE; RECEPTORS, CHOLINERGIC; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84931024513     PISSN: 21686149     EISSN: 21686157     Source Type: Journal    
DOI: 10.1001/jamaneurol.2015.0203     Document Type: Article

References (37)

1. Lindstrom JM, Seybold ME, Lennon VA, Whittingham S, Duane DD. Antibody to acetylcholine receptor inmyasthenia gravis: prevalence, clinical correlates, and diagnostic value. Neurology. 1976;26(11):1054-1059.
2. Vincent A, Newsom-Davis J. Acetylcholine receptor antibody as a diagnostic test for myasthenia gravis: results in 153 validated cases and 2967 diagnostic assays. J Neurol Neurosurg Psychiatry. 1985;48(12):1246-1252.
3. Vincent A. Unravelling the pathogenesis of myasthenia gravis. Nat Rev Immunol. 2002;2(10):797-804.
4. Soliven BC, Lange DJ, Penn AS, et al. Seronegativemyasthenia gravis. Neurology. 1988;38(4):514-517.
5. Hoch W, McConville J, Helms S, Newsom-Davis J, Melms A, Vincent A. Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies. Nat Med. 2001;7(3):365-368.
6. Scuderi F, Marino M, Colonna L, et al. Anti-p110 autoantibodies identify a subtype of "seronegative" myasthenia gravis with prominent oculobulbar involvement. Lab Invest. 2002;82(9):1139-1146.
7. Shiraishi H, Motomura M, Yoshimura T, et al. Acetylcholine receptors loss and postsynaptic damage in MuSK antibody-positivemyasthenia gravis. Ann Neurol. 2005;57(2):289-293.
8. Chang T, Gunaratne P, Gamage R, Riffsy MT, Vincent A. MuSK-antibody-positivemyasthenia gravis in a South Asian population. J Neurol Sci. 2009;284(1-2):33-35.
9. Kostera-Pruszczyk A, Kamińska A, Dutkiewicz M, et al. MuSK-positivemyasthenia gravis is rare in the Polish population. Eur J Neurol. 2008;15(7):720-724.
10. Illa I, Díaz-Manera JA, Juárez C, et al. "Seronegative" myasthenia gravis and antiMuSK positive antibodies: description of Spanish series [in Spanish]. Med Clin (Barc). 2005;125(3):100-102.
11. Romi F, Aarli JA, Gilhus NE. Seronegative myasthenia gravis: disease severity and prognosis. Eur J Neurol. 2005;12(6):413-418.
12. Niks EH, Kuks JB, Verschuuren JJ. Epidemiology of myasthenia gravis with anti-muscle specific kinase antibodies in the Netherlands. J Neurol Neurosurg Psychiatry. 2007;78(4):417-418.
13. Koneczny I, Cossins J, Waters P, Beeson D, Vincent A. MuSKmyasthenia gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters. PLoS One. 2013;8(11):e80695. doi:10.1371/journal.pone.0080695.
14. Sanders DB, El-Salem K, Massey JM, McConville J, Vincent A. Clinical aspects of MuSK antibody positive seronegative MG. Neurology. 2003;60(12):1978-1980.
15. Evoli A, Tonali PA, Padua L, et al. Clinical correlates with anti-MuSK antibodies in generalized seronegativemyasthenia gravis. Brain. 2003;126(pt 10):2304-2311.
16. Leite MI, Jacob S, Viegas S, et al. IgG1 antibodies to acetylcholine receptors in "seronegative" myasthenia gravis. Brain. 2008;131(pt 7):1940-1952.
17. Jacob S, Viegas S, Leite MI, et al. Presence and pathogenic relevance of antibodies to clustered acetylcholine receptor in ocular and generalized myasthenia gravis. Arch Neurol. 2012;69(8):994-1001.
18. Devic P, Petiot P, Simonet T, et al. Antibodies to clustered acetylcholine receptor: expanding the phenotype. Eur J Neurol. 2014;21(1):130-134.
19. Zhang B, Shen C, Bealmear B, et al. Autoantibodies to agrin inmyasthenia gravis patients. PLoS One. 2014;9(3):e91816. doi:10.1371/journal.pone.0091816.
20. Gasperi C, Melms A, Schoser B, et al. Anti-agrin autoantibodies inmyasthenia gravis. Neurology. 2014;82(22):1976-1983.
21. Pevzner A, Schoser B, Peters K, et al. Anti-LRP4 autoantibodies in AChR- and MuSK-antibody-negativemyasthenia gravis. J Neurol. 2012;259(3):427-435.
22. Zisimopoulou P, Evangelakou P, Tzartos J, et al. A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 inmyasthenia gravis. J Autoimmun. 2014;52:139-145.
23. Cossins J, Belaya K, Zoltowska K, et al. The search for new antigenic targets inmyasthenia gravis. Ann N Y Acad Sci. 2012;1275:123-128.
24. Jaretzki A III, Barohn RJ, Ernstoff RM, et al; Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Myasthenia gravis: recommendations for clinical research standards. Neurology. 2000;55(1):16-23.
25. Beghi E, Antozzi C, Batocchi AP, et al. Prognosis of myasthenia gravis: a multicenter follow-up study of 844 patients. J Neurol Sci. 1991;106(2):213-220.
26. Mantegazza R, Baggi F, Antozzi C, et al. Myasthenia gravis (MG): epidemiological data and prognostic factors. Ann N Y Acad Sci. 2003;998:413-423.
27. Chang T, Leite MI, Senanayake S, et al. Clinical and serological study of myasthenia gravis using both radioimmunoprecipitation and cell-based assays in a South Asian population. J Neurol Sci. 2014;343(1-2):82-87.
28. Ashraf VV, Taly AB, Veerendrakumar M, Rao S. Myasthenia gravis in children: a longitudinal study. Acta Neurol Scand. 2006;114(2):119-123.
29. Chiang LM, Darras BT, Kang PB. Juvenile myasthenia gravis. Muscle Nerve. 2009;39(4):423-431.
30. Andrews PI, Massey JM, Howard JF Jr, Sanders DB. Race, sex, and puberty influence onset, severity, and outcome in juvenilemyasthenia gravis. Neurology. 1994;44(7):1208-1214.
31. Pineles SL, Avery RA, Moss HE, et al. Visual and systemic outcomes in pediatric ocularmyasthenia gravis. Am J Ophthalmol. 2010;150(4):453-459.e3. doi:10.1016/j.ajo.2010.05.002.
32. Andrews PI, Massey JM, Sanders DB. Acetylcholine receptor antibodies in juvenile myasthenia gravis. Neurology. 1993;43(5):977-982.
33. Parr JR, Andrew MJ, Finnis M, Beeson D, Vincent A, Jayawant S. How common is childhood myasthenia? the UK incidence and prevalence of autoimmune and congenitalmyasthenia. Arch Dis Child. 2014;99(6):539-542.
34. Heng HS, Lim M, Absoud M, et al. Outcome of children with acetylcholine receptor (AChR) antibody positive juvenilemyasthenia gravis following thymectomy. Neuromuscul Disord. 2014;24(1):25-30.
35. Ionita CM, Acsadi G. Management of juvenile myasthenia gravis. Pediatr Neurol. 2013;48(2):95-104.
36. Chiu HC, Vincent A, Newsom-Davis J, Hsieh KH, Hung T. Myasthenia gravis: population differences in disease expression and acetylcholine receptor antibody titers between Chinese and Caucasians. Neurology. 1987;37(12):1854-1857.
37. Zhang X, Yang M, Xu J, et al. Clinical and serological study of myasthenia gravis in Hu Bei Province, China. J Neurol Neurosurg Psychiatry. 2007;78(4):386-390.